CureToday: UC enrolling patients for glioblastoma trial

A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.

Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.

In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.

Read the article.

Read more about the trial.

For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.

Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.

Related Stories

2

UC expert helps rehome endangered Ohio bats

August 19, 2026

UC College of Education, Criminal Justice, and Human Services Assistant Professor Joe Johnson is helping an Ohio marine rehome bats to make way for renovations. He launched a new tracking project that uses tiny transmitters that record bat migration using the internet of things.

3

Emeritus professor honored for gas turbine research

August 17, 2026

Mark Turner has been part of the University of Cincinnati's College of Engineering and Applied Science for 25 years. His work in the field of gas turbine simulation and design continues to leave a significant impact on the industry. He was honored by the American Society of Mechanical Engineers with the International Gas Turbine Institute Scholar Award. Turner is part of the Department of Aerospace Engineering and Engineering Mechanics at UC.